M.D., Medical University of South Carolina, 1980.
Ph.D., Medical University of South Carolina, 1978.
Protection and Control of HIV-1 Infection by T Cell Immunity.
Our laboratory seeks to identify the components of immunity that are important in preventing and controlling HIV-1 infection. Our goal is to understand how T cell memory is induced both in natural infection and by immunization, and to identify the properties of T cells that confer containment or eradiation of HIV-1.
Our studies encompass a broad range of immunologic investigations in persons who experience unusual control of HIV-1 infection. These include individuals with newly diagnosed infection, those with long-term non-progressive disease who control infection for more than a decade without antiretroviral treatment, and individuals repeatedly exposed but not infected. These clinical cohorts have been assembled for longitudinal studies in both Seattle and in countries where the HIV epidemic is widespread (South Africa, Uganda). Most recent studies focus on African HIV discordant couples, providing a unique opportunity to address host characteristics that lead to altered susceptibility to infection and transmission. In addition, we have targeted studies to gain further understanding of how HIV-1 gains entry into the mucosa and the induction of HIV-specific mucosal immunity.
We also devote extensive efforts to HIV-1 vaccine development. First, we lead a large collaborative project to identify innate immune mechanisms that may enhance adaptive immunological memory to HIV. Further, our laboratory program oversees the evaluation of multiple candidate vaccines in a international vaccine network, which provides basic insights into how different vaccine modalities elicit optimal B- and T-cell immunity to HIV-1 that may be ultimately protective against infection and disease.
American College of Physicians
Association of American Physicians
National Institute of Health AIDS Vaccine Research Subcommittee
Honors and Awards
2008, M. Juliana McElrath, American College of Physicians, Fellowship
2000-2006, M. Juliana McElrath, Burroughs Wellcome, Clinical Scientist Award in Translational Research
1997, M. Juliana McElrath, National Institutes of Health (NIH), National Institutes of Health (NIH), Merit Award
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine.. 2013.
Differential Regulatory T Cell Activity in HIV Type 1-Exposed Seronegative Individuals.. AIDS research and human retroviruses.. 2013.
Progress in HIV-1 vaccine development.. Current opinion in HIV and AIDS. 8(4):326-32.. 2013.
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001).. The Journal of infectious diseases. 207(2):248-56.. 2013.
Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+ T Cells Induced by Different Adenovirus Vectors.. Journal of virology. 87(3):1359-72.. 2013.
Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials.. Journal of immunological methods. 394(1-2):84-93.. 2013.
Human CD1a Deficiency Is Common and Genetically Regulated.. Journal of immunology (Baltimore, Md. : 1950). 191(4):1586-93.. 2013.
Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection.. The Journal of infectious diseases.. 2013.
A Blueprint for HIV Vaccine Discovery.. Cell host & microbe. 12(4):396-407.. 2012.
Quantifying Ongoing HIV-1 Exposure in HIV-1-Serodiscordant Couples to Identify Individuals With Potential Host Resistance to HIV-1.. The Journal of infectious diseases. 206(8):1299-1308.. 2012.
Vpu mediates IRF3 depletion during HIV infection by a lysosomal-dependent mechanism.. Journal of virology.. 2012.
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.. Clinical investigation. 2(3):245-254.. 2012.
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67.. 2012.
Profiling immunity to HIV vaccines with systems biology.. Current opinion in HIV and AIDS. 7(1):32-37.. 2012.
Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity.. Proceedings of the National Academy of Sciences of the United States of America. 109(50):E3503-12.. 2012.
OMIP-014: Validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining.. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 81(12):1019-21.. 2012.
Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells.. Journal of immunological methods. 382(1-2):117-28.. 2012.
Is an HIV vaccine possible? Journal of acquired immune deficiency syndromes (1999). 60 Suppl 2:S41-3.. 2012.
Vpu deficient HIV strains stimulate innate immune signaling responses in target cells.. Journal of virology. 86(16):8499-506.. 2012.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86.. 2012.
Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay.. Journal of visualized experiments : JoVE. (67):e4302.. 2012.